biostudies-literature00390Unknown11(3)Bukhari NDihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report cases from our institute with colorectal cancer who experienced severe toxicities to standard dose 5-FU based chemotherapy. <i>DPYD</i> gene sequencing revealed rare different polymorphisms that prompted dose adjustments of administered 5-FU and capecitabine. To our knowledge, this is the first case series looking at <i>DPYD</i> polymorphisms in the Saudi Arabian population.Clinics and practice467-471https://www.ebi.ac.uk/biostudies/studies/S-EPMC8395516biostudies-literatureFluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature.PMC8395516Al-Khallaf HAlshangiti ATashkandi EAlgarni MAl-Shamsi HOBukhari N39falseFluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature.Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report cases from our institute with colorectal cancer who experienced severe toxicities to standard dose 5-FU based chemotherapy. <i>DPYD</i> gene sequencing revealed rare different polymorphisms that prompted dose adjustments of administered 5-FU and capecitabine. To our knowledge, this is the first case series looking at <i>DPYD</i> polymorphisms in the Saudi Arabian population.2021-01-01T00:00:00Z2021 Jul2024-10-19T07:10:33.738Z2022-02-11T09:55:28.72ZS-EPMC83955163444954010.3390/clinpract11030062